Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D, Le Chevalier T; LACE Collaborative Group..

J Clin Oncol. 2008 Jul 20;26(21):3552-9. doi: 10.1200/JCO.2007.13.9030.

PMID:
18506026
2.

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P.

Lancet Oncol. 2006 Sep;7(9):719-27. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.

PMID:
16945766
3.

Vinorelbine and cisplatin in advanced squamous cell carcinoma of the cervix: the South African experience.

Goedhals L, Falkson G, Smith BL, Falkson CI, Gasmi J, Lategan A, Burillon JP, His P.

Anticancer Res. 2005 May-Jun;25(3c):2489-92.

4.

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy.

Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V.

J Clin Oncol. 2003 Jan 1;21(1):35-40.

PMID:
12506167

Supplemental Content

Loading ...
Support Center